a Ocular Inflammation/Immunology Service , Genimatas General Hospital , Athens , Greece.
b First Department of Propaedeutic Internal Medicine & Joint Academic Rheumatology Program , National and Kapodistrian University of Athens, Medical School , Athens , Greece.
Ocul Immunol Inflamm. 2019;27(1):51-57. doi: 10.1080/09273948.2017.1332228. Epub 2017 Jul 12.
Relapsing ocular inflammation occurs in about 70% of patients with Behçet's disease (BD) and can lead to permanent loss of vision. Neovascularization of the optic disc (NVD) or elsewhere in the retina (NVE) is a relatively uncommon but severe complication that lacks standardized treatment.
We report on the therapeutic use of anti-TNF monoclonal antibodies for BD-associated NVD and NVE in one pediatric patient (subcutaneous adalimumab) and one young man (intravenous infliximab). Also, we review the previously published experience on biologic therapeutic options, namely anti-TNF agents and interferon-alpha in a total of three and eight patients, respectively.
A fast-onset therapeutic effect was observed in both patients leading to complete regression of neovascularizations.
Both options may lead to regression of neovascularization, thus preventing loss of vision, but comparative studies need to determine the optimal treatment for this sight-threatening complication of BD.
约 70%的贝赫切特病（BD）患者会出现眼部炎症复发，这可能导致永久性视力丧失。视盘新生血管（NVD）或视网膜其他部位的新生血管（NVE）是一种相对罕见但严重的并发症，缺乏标准化的治疗方法。
我们报告了一例儿科患者（皮下阿达木单抗）和一例年轻男性（静脉注射英夫利昔单抗）使用抗 TNF 单克隆抗体治疗 BD 相关 NVD 和 NVE 的情况。此外，我们还回顾了之前发表的关于生物治疗选择的经验，即抗 TNF 药物和干扰素-α，分别在三例和八例患者中进行了研究。
两名患者均观察到快速起效的治疗效果，导致新生血管完全消退。
这两种方法都可能使新生血管消退，从而防止视力丧失，但需要进行比较研究以确定治疗 BD 这种威胁视力的并发症的最佳方法。
